Pluristem Therapeutics Inc (PSTI)

[PLX-11]

"In April, Pluristem received U.S. Food and Drug Administration clearance for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle injury following surgical repair. PLX stands for “placental expanded,” while PAD refers to placental-derived adherent or mesenchymal stromal cells.

That’s a type of stem cell that can be used for numerous purposes in the body.

“We were the only site to be selected that is not academic,” Boyer said. “This is the first patient in the United States and the first patient enrolled in this trial.”


https://www.indianagazette.com/news/irmc-patient-receives-historic-stem-cell-surgery/article_a1183e66-3766-5fb0-b7d3-af7fd15d8c1e.html?utm_medium=social&utm_source=facebook&utm_campaign=user-share